Desidustat vs Vadadustat
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Kidney Disease
Shared mechanism: HIF prolyl hydroxylase (HIF-PH1/2/3) · full Chronic Kidney Disease pipeline
Desidustat · Oxemia
Marketed by Zydus Lifesciences and partners
NCT04012957 · Phase 3 · completed
The study was randomized and used an active darbepoetin comparator, but it was open-label and its primary outcome was change in hemoglobin, a surrogate laboratory measure rather than a hard clinical or endoscopic outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Reported efficacy
Hemoglobin level (24 weeks): Change in hemoglobin baseline to week 16-24: desidustat +0.95 g/dL vs epoetin alfa +0.80 g/dL (difference 0.14 g/dL, 95% CI -0.13 to 0.42), met prespecified noninferiority margin; hemoglobin responders 59.22% desidustat vs 48.37% epoetin alfa (p=0.0382) (met)
Result source: NCT04215120
Vadadustat · Vafseo
Marketed by Akebia Therapeutics and partners
NCT02648347 · Phase 3 · completed
Participants were randomized to vadadustat or active treatment with darbepoetin alfa, but the trial was open-label; 879 received vadadustat and 872 received darbepoetin alfa. The hemoglobin primary endpoint met the prespecified non-inferiority criterion, while the primary cardiovascular safety comparison did not, making the findings mixed rather than clearly positive.
Next expected readout: April 2027 · NCT07565701 (registry estimate)
Reported efficacy
Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36) (Baseline; Weeks 24 to 36); Median Time to First Major Adverse Cardiovascular Event (MACE) (Up to Week 208): Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36) (Baseline; Weeks 24 to 36): Vadadustat 0.41 Grams per deciliter (g/dL) (Standard Error 0.036) vs Darbepoetin Alfa 0.42 Grams per deciliter (g/dL) (Standard Error 0.037) (mixed)
Result source: NCT02680574
Results for Chronic Kidney Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Desidustat | Vadadustat |
|---|---|---|
| Kidney composite outcome | —Not posted · NCT04012957 | —Not posted · NCT02892149 |
| UACR, % change | —Not posted · NCT04012957 | —Not posted · NCT02892149 |
| eGFR slope | —Not posted · NCT04012957 | —Not posted · NCT02892149 |
| Haemoglobin, change | 1.9 vs 1.8avs darbepoetinNCT040129571 other result
| 1.4 vs 1.4vs Darbepoetin AlfaNCT0264834734 other results
|
Kidney composite outcome
- Desidustat
- —Not posted · NCT04012957
- Vadadustat
- —Not posted · NCT02892149
UACR, % change
- Desidustat
- —Not posted · NCT04012957
- Vadadustat
- —Not posted · NCT02892149
eGFR slope
- Desidustat
- —Not posted · NCT04012957
- Vadadustat
- —Not posted · NCT02892149
Haemoglobin, change
- Desidustat
- 1.9 vs 1.8avs darbepoetinNCT04012957
1 other result
- 0.9 vs 0.8 NCT04215120
- Vadadustat
- 1.4 vs 1.4vs Darbepoetin AlfaNCT02648347
34 other results
- 0.4 vs 0.4 NCT02680574
- 1.5 vs 1.5 NCT02648347
- 0.2 vs 0.4 NCT02892149
- 1.4 vs 1.5 NCT02865850
- 0.9 vs -0.1 NCT01906489
- 0.7 vs -0.2 NCT01906489
- 0.8 vs -0.2 NCT01906489
- 0.9 vs -0.2 NCT01906489
- 0.7 vs -0.4 NCT01906489
- 0.6 vs -0.4 NCT01906489
- 0.4 vs -0.3 NCT01906489
- 0.1 vs -0.2 NCT01906489
- 1.4 vs -0.0 NCT01381094
- 1.1 vs 0.1 NCT01381094
- 0.5 vs 0.1 NCT01381094
- 0.3 vs 0.0 NCT01381094
- 1.3 vs -0.0 NCT01381094
- 0.8 vs 0.1 NCT01381094
- 0.5 vs 0.1 NCT01381094
- 0.3 vs 0.0 NCT01381094
- 0.7 vs -0.0 NCT01381094
- 0.4 vs 0.1 NCT01381094
- 0 vs 0.1 NCT01381094
- -0.1 vs 0.0 NCT01381094
- 0.8 vs -0.0 NCT01381094
- 0.5 vs 0.1 NCT01381094
- 0.2 vs 0.1 NCT01381094
- 0.1 vs 0.0 NCT01381094
- -0.2 vs 0.1 NCT03799627
- -0.2 vs 0.1 NCT03799627
- 0.1 vs 0.1 NCT03799627
- -0.5 vs 0.1 NCT03799627
- -0.4 vs 0.1 NCT03799627
- -0.3 vs 0.1 NCT03799627
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. Desidustat: 1 of 5 rows · Vadadustat: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Desidustat | Vadadustat Rows use multiple source trials |
|---|---|---|
| Hemoglobin responder rate · % of participants | 77.78% vs 68.48% darbepoetina,b,c,d NCT04012957 · Phase 3 · sponsor-reported, not registry data 1 other source trial59.22% vs 48.37% epoetin alfa NCT04215120 · Phase 3 · sponsor-reported, not registry data | 42.9% (n=7) vs 60.9% (n=23) Epoetin Alfa @ 20wk*300 mge,a,b,c,d NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 3 Participants as posted show 5 more doses38.5% (n=26) vs 60.9% (n=23) Epoetin Alfa @ 20wk*300 mg NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 10 Participants as posted 33.3% (n=3) vs 60.9% (n=23) Epoetin Alfa @ 20wk*600 mg NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 1 Participants as posted 20% (n=10) vs 60.9% (n=23) Epoetin Alfa @ 20wk*600 mg NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 2 Participants as posted 35.7% (n=14) vs 60.9% (n=23) Epoetin Alfa @ 20wk*450 mg NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 5 Participants as posted 45.8% (n=24) vs 60.9% (n=23) Epoetin Alfa @ 20wk*450 mg NCT03799627 · Phase 2 · registry result, not featured evidence · converted to % from 11 Participants as posted |
| Dropout rate | — | 23.8%f NCT02648347 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 show 46 more results18.3% NCT02680574 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 11.6% NCT02865850 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 19.8% NCT02892149 · Phase 3 35.5%900 mg TIW NCT04707768 · Phase 3 · registry result, not featured evidence 34.9%600 mg TIW NCT04707768 · Phase 3 · registry result, not featured evidence 55.6%300 mg NCT03799627 · Phase 2 · registry result, not featured evidence 22.9%300 mg NCT03799627 · Phase 2 · registry result, not featured evidence 40%600 mg NCT03799627 · Phase 2 · registry result, not featured evidence 61.9%600 mg NCT03799627 · Phase 2 · registry result, not featured evidence 42.9%450 mg NCT03799627 · Phase 2 · registry result, not featured evidence 32.4%450 mg NCT03799627 · Phase 2 · registry result, not featured evidence —300 mg NCT03054350 · Phase 2 · registry result, not featured evidence —300 mg NCT03054350 · Phase 2 · registry result, not featured evidence 80%300 mg NCT03054350 · Phase 2 · registry result, not featured evidence —300 mg NCT03054350 · Phase 2 · registry result, not featured evidence 13.3%300 mg NCT03054350 · Phase 2 · registry result, not featured evidence —600 mg NCT03054350 · Phase 2 · registry result, not featured evidence —600 mg NCT03054350 · Phase 2 · registry result, not featured evidence 60%600 mg NCT03054350 · Phase 2 · registry result, not featured evidence —600 mg NCT03054350 · Phase 2 · registry result, not featured evidence 13.3%600 mg NCT03054350 · Phase 2 · registry result, not featured evidence —150 mg NCT03054350 · Phase 2 · registry result, not featured evidence —150 mg NCT03054350 · Phase 2 · registry result, not featured evidence 40%150 mg NCT03054350 · Phase 2 · registry result, not featured evidence —150 mg NCT03054350 · Phase 2 · registry result, not featured evidence 26.7%150 mg NCT03054350 · Phase 2 · registry result, not featured evidence —300 mg NCT03054337 · Phase 2 · registry result, not featured evidence —300 mg NCT03054337 · Phase 2 · registry result, not featured evidence 0%300 mg NCT03054337 · Phase 2 · registry result, not featured evidence —600 mg NCT03054337 · Phase 2 · registry result, not featured evidence —600 mg NCT03054337 · Phase 2 · registry result, not featured evidence 0%600 mg NCT03054337 · Phase 2 · registry result, not featured evidence —150 mg NCT03054337 · Phase 2 · registry result, not featured evidence —150 mg NCT03054337 · Phase 2 · registry result, not featured evidence 0%150 mg NCT03054337 · Phase 2 · registry result, not featured evidence 20%300 mg Once Daily (QD) NCT02260193 · Phase 2 · registry result, not featured evidence 32.3%450 mg 3 Times Per Week (TIW) NCT02260193 · Phase 2 · registry result, not featured evidence 27.3%450 mg QD NCT02260193 · Phase 2 · registry result, not featured evidence 18.8% NCT01906489 · Phase 2 · registry result, not featured evidence 5.3%630 mg NCT01381094 · Phase 2 · registry result, not featured evidence 0%500 mg NCT01381094 · Phase 2 · registry result, not featured evidence 16.7%370 mg NCT01381094 · Phase 2 · registry result, not featured evidence 11.1%240 mg NCT01381094 · Phase 2 · registry result, not featured evidence 0% NCT01235936 · Phase 2 · registry result, not featured evidence 0%Cohort 1: CKD Stage 3 Vadadustat NCT04707573 · Phase 2 · registry result, not featured evidence 0%Cohort 2: CKD Stage 4 Vadadustat NCT04707573 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | — | —f NCT02648347 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 show 46 more results— NCT02680574 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 — NCT02865850 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 — NCT02892149 · Phase 3 11.8%900 mg TIW NCT04707768 · Phase 3 · registry result, not featured evidence 5.9%600 mg TIW NCT04707768 · Phase 3 · registry result, not featured evidence 0%300 mg NCT03799627 · Phase 2 · registry result, not featured evidence 2.9%300 mg NCT03799627 · Phase 2 · registry result, not featured evidence 40%600 mg NCT03799627 · Phase 2 · registry result, not featured evidence 23.8%600 mg NCT03799627 · Phase 2 · registry result, not featured evidence 9.5%450 mg NCT03799627 · Phase 2 · registry result, not featured evidence 5.9%450 mg NCT03799627 · Phase 2 · registry result, not featured evidence —300 mg NCT03054350 · Phase 2 · registry result, not featured evidence —300 mg NCT03054350 · Phase 2 · registry result, not featured evidence —300 mg NCT03054350 · Phase 2 · registry result, not featured evidence —300 mg NCT03054350 · Phase 2 · registry result, not featured evidence —300 mg NCT03054350 · Phase 2 · registry result, not featured evidence —600 mg NCT03054350 · Phase 2 · registry result, not featured evidence —600 mg NCT03054350 · Phase 2 · registry result, not featured evidence —600 mg NCT03054350 · Phase 2 · registry result, not featured evidence —600 mg NCT03054350 · Phase 2 · registry result, not featured evidence —600 mg NCT03054350 · Phase 2 · registry result, not featured evidence —150 mg NCT03054350 · Phase 2 · registry result, not featured evidence —150 mg NCT03054350 · Phase 2 · registry result, not featured evidence —150 mg NCT03054350 · Phase 2 · registry result, not featured evidence —150 mg NCT03054350 · Phase 2 · registry result, not featured evidence —150 mg NCT03054350 · Phase 2 · registry result, not featured evidence —300 mg NCT03054337 · Phase 2 · registry result, not featured evidence —300 mg NCT03054337 · Phase 2 · registry result, not featured evidence —300 mg NCT03054337 · Phase 2 · registry result, not featured evidence —600 mg NCT03054337 · Phase 2 · registry result, not featured evidence —600 mg NCT03054337 · Phase 2 · registry result, not featured evidence —600 mg NCT03054337 · Phase 2 · registry result, not featured evidence —150 mg NCT03054337 · Phase 2 · registry result, not featured evidence —150 mg NCT03054337 · Phase 2 · registry result, not featured evidence —150 mg NCT03054337 · Phase 2 · registry result, not featured evidence 10%300 mg Once Daily (QD) NCT02260193 · Phase 2 · registry result, not featured evidence 3.2%450 mg 3 Times Per Week (TIW) NCT02260193 · Phase 2 · registry result, not featured evidence 12.1%450 mg QD NCT02260193 · Phase 2 · registry result, not featured evidence 7.2% NCT01906489 · Phase 2 · registry result, not featured evidence 5.3%630 mg NCT01381094 · Phase 2 · registry result, not featured evidence 0%500 mg NCT01381094 · Phase 2 · registry result, not featured evidence 11.1%370 mg NCT01381094 · Phase 2 · registry result, not featured evidence 5.6%240 mg NCT01381094 · Phase 2 · registry result, not featured evidence — NCT01235936 · Phase 2 · registry result, not featured evidence —Cohort 1: CKD Stage 3 Vadadustat NCT04707573 · Phase 2 · registry result, not featured evidence —Cohort 2: CKD Stage 4 Vadadustat NCT04707573 · Phase 2 · registry result, not featured evidence |
| Serious AEs | — | 65.3%f NCT02648347 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 show 46 more results58.5% NCT02680574 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 49.7% NCT02865850 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 55% NCT02892149 · Phase 3 44%900 mg TIW NCT04707768 · Phase 3 · registry result, not featured evidence 45%600 mg TIW NCT04707768 · Phase 3 · registry result, not featured evidence 44.4%300 mg NCT03799627 · Phase 2 · registry result, not featured evidence 26.5%300 mg NCT03799627 · Phase 2 · registry result, not featured evidence 80%600 mg NCT03799627 · Phase 2 · registry result, not featured evidence 47.6%600 mg NCT03799627 · Phase 2 · registry result, not featured evidence 28.6%450 mg NCT03799627 · Phase 2 · registry result, not featured evidence 20%450 mg NCT03799627 · Phase 2 · registry result, not featured evidence 6.7%300 mg NCT03054350 · Phase 2 · registry result, not featured evidence 0%300 mg NCT03054350 · Phase 2 · registry result, not featured evidence —300 mg NCT03054350 · Phase 2 · registry result, not featured evidence 0%300 mg NCT03054350 · Phase 2 · registry result, not featured evidence —300 mg NCT03054350 · Phase 2 · registry result, not featured evidence 6.7%600 mg NCT03054350 · Phase 2 · registry result, not featured evidence 0%600 mg NCT03054350 · Phase 2 · registry result, not featured evidence —600 mg NCT03054350 · Phase 2 · registry result, not featured evidence 20%600 mg NCT03054350 · Phase 2 · registry result, not featured evidence —600 mg NCT03054350 · Phase 2 · registry result, not featured evidence 6.7%150 mg NCT03054350 · Phase 2 · registry result, not featured evidence 0%150 mg NCT03054350 · Phase 2 · registry result, not featured evidence —150 mg NCT03054350 · Phase 2 · registry result, not featured evidence 0%150 mg NCT03054350 · Phase 2 · registry result, not featured evidence —150 mg NCT03054350 · Phase 2 · registry result, not featured evidence 41.7%300 mg NCT03054337 · Phase 2 · registry result, not featured evidence 0%300 mg NCT03054337 · Phase 2 · registry result, not featured evidence —300 mg NCT03054337 · Phase 2 · registry result, not featured evidence 15.4%600 mg NCT03054337 · Phase 2 · registry result, not featured evidence 0%600 mg NCT03054337 · Phase 2 · registry result, not featured evidence —600 mg NCT03054337 · Phase 2 · registry result, not featured evidence 0%150 mg NCT03054337 · Phase 2 · registry result, not featured evidence 0%150 mg NCT03054337 · Phase 2 · registry result, not featured evidence —150 mg NCT03054337 · Phase 2 · registry result, not featured evidence 16.7%300 mg Once Daily (QD) NCT02260193 · Phase 2 · registry result, not featured evidence 25.8%450 mg 3 Times Per Week (TIW) NCT02260193 · Phase 2 · registry result, not featured evidence 27.3%450 mg QD NCT02260193 · Phase 2 · registry result, not featured evidence 23.9% NCT01906489 · Phase 2 · registry result, not featured evidence 5.3%630 mg NCT01381094 · Phase 2 · registry result, not featured evidence 5.9%500 mg NCT01381094 · Phase 2 · registry result, not featured evidence 16.7%370 mg NCT01381094 · Phase 2 · registry result, not featured evidence 11.1%240 mg NCT01381094 · Phase 2 · registry result, not featured evidence 0% NCT01235936 · Phase 2 · registry result, not featured evidence 0%Cohort 1: CKD Stage 3 Vadadustat NCT04707573 · Phase 2 · registry result, not featured evidence 0%Cohort 2: CKD Stage 4 Vadadustat NCT04707573 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | — | f hypertension 17.2% diarrhoea 13% oedema peripheral 12.5% NCT02648347 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 show 37 more resultshypertension 13.9% diarrhoea 13.6% urinary tract infection 10.8% NCT02680574 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 hypertension 15.1% diarrhoea 10.1% nausea 7.8% NCT02865850 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 900 mg TIW diarrhoea 14% covid 19 12% hyperkalaemia 8.7% NCT04707768 · Phase 3 · registry result, not featured evidence 600 mg TIW covid 19 12.6% diarrhoea 10.6% nausea 7.9% NCT04707768 · Phase 3 · registry result, not featured evidence 300 mg diarrhoea 22.2% fall 11.1% hyperkalaemia 11.1% NCT03799627 · Phase 2 · registry result, not featured evidence 300 mg cough 5.9% headache 5.9% influenza 5.9% NCT03799627 · Phase 2 · registry result, not featured evidence 600 mg acarodermatitis 20% anaemia 20% back pain 20% NCT03799627 · Phase 2 · registry result, not featured evidence 600 mg diarrhoea 19% headache 14.3% hypertension 14.3% NCT03799627 · Phase 2 · registry result, not featured evidence 450 mg arteriovenous fistula thrombosis 9.5% diarrhoea 9.5% fall 4.8% NCT03799627 · Phase 2 · registry result, not featured evidence 450 mg diarrhoea 8.6% hypertension 8.6% nasopharyngitis 8.6% NCT03799627 · Phase 2 · registry result, not featured evidence 300 mg nasopharyngitis 13.3% (placebo 0%) asthma 6.7% (placebo 0%) cholelithiasis 6.7% (placebo 0%) NCT03054350 · Phase 2 · registry result, not featured evidence 300 mg blood uric acid decreased 20% (placebo 0%) nasopharyngitis 20% (placebo 0%) abdominal pain 0% (placebo 0%) NCT03054350 · Phase 2 · registry result, not featured evidence 300 mg nasopharyngitis 33.3% (placebo 0%) diarrhoea 13.3% (placebo 20%) blood parathyroid hormone increased 6.7% (placebo 0%) NCT03054350 · Phase 2 · registry result, not featured evidence 600 mg anaemia macrocytic 6.7% (placebo 0%) cardiac failure chronic 6.7% (placebo 0%) dermal cyst 6.7% (placebo 0%) NCT03054350 · Phase 2 · registry result, not featured evidence 600 mg catheter site erosion 20% (placebo 0%) conjunctivitis 20% (placebo 0%) diarrhoea 20% (placebo 20%) NCT03054350 · Phase 2 · registry result, not featured evidence 600 mg diarrhoea 13.3% (placebo 20%) abdominal pain 6.7% (placebo 0%) contusion 6.7% (placebo 0%) NCT03054350 · Phase 2 · registry result, not featured evidence 150 mg nasopharyngitis 26.7% (placebo 0%) contusion 13.3% (placebo 0%) headache 13.3% (placebo 0%) NCT03054350 · Phase 2 · registry result, not featured evidence 150 mg diarrhoea 20% (placebo 20%) headache 20% (placebo 0%) pneumonia 20% (placebo 0%) NCT03054350 · Phase 2 · registry result, not featured evidence 150 mg arthralgia 6.7% (placebo 20%) constipation 6.7% (placebo 0%) cough 6.7% (placebo 0%) NCT03054350 · Phase 2 · registry result, not featured evidence 300 mg constipation 16.7% (placebo 0%) abdominal distension 8.3% (placebo 0%) abdominal pain 8.3% (placebo 0%) NCT03054337 · Phase 2 · registry result, not featured evidence 300 mg hypertension 25% (placebo 0%) nausea 16.7% (placebo 0%) angular cheilitis 8.3% (placebo 0%) NCT03054337 · Phase 2 · registry result, not featured evidence 600 mg benign prostatic hyperplasia 7.7% (placebo 0%) delirium 7.7% (placebo 0%) diarrhoea 7.7% (placebo 0%) NCT03054337 · Phase 2 · registry result, not featured evidence 600 mg hypertension 15.4% (placebo 0%) aspartate aminotransferase increased 7.7% (placebo 0%) back pain 7.7% (placebo 0%) NCT03054337 · Phase 2 · registry result, not featured evidence 150 mg contusion 16.7% (placebo 0%) abdominal distension 8.3% (placebo 0%) back pain 8.3% (placebo 0%) NCT03054337 · Phase 2 · registry result, not featured evidence 150 mg influenza 8.3% (placebo 0%) oedema due to renal disease 8.3% (placebo 0%) orthostatic hypotension 8.3% (placebo 0%) NCT03054337 · Phase 2 · registry result, not featured evidence 300 mg Once Daily (QD) diarrhoea 13.3% nausea 13.3% arteriovenous fistula site complication 10% NCT02260193 · Phase 2 · registry result, not featured evidence 450 mg 3 Times Per Week (TIW) nausea 12.9% back pain 9.7% headache 9.7% NCT02260193 · Phase 2 · registry result, not featured evidence 450 mg QD abdominal pain 12.1% diarrhoea 12.1% dizziness 9.1% NCT02260193 · Phase 2 · registry result, not featured evidence diarrhoea 10.1% (placebo 4.2%) nausea 10.1% (placebo 4.2%) fatigue 8% (placebo 6.9%) NCT01906489 · Phase 2 · registry result, not featured evidence 630 mg hypertension 10.5% (placebo 15.8%) abdominal pain 5.3% (placebo 0%) adverse drug reaction 5.3% (placebo 0%) NCT01381094 · Phase 2 · registry result, not featured evidence 500 mg hyperkalaemia 17.6% (placebo 5.3%) nausea 11.8% (placebo 10.5%) blood bicarbonate decreased 5.9% (placebo 0%) NCT01381094 · Phase 2 · registry result, not featured evidence 370 mg abdominal discomfort 5.6% (placebo 0%) abdominal pain upper 5.6% (placebo 0%) blood uric acid increased 5.6% (placebo 0%) NCT01381094 · Phase 2 · registry result, not featured evidence 240 mg headache 11.1% (placebo 0%) urinary tract infection 11.1% (placebo 0%) constipation 5.6% (placebo 0%) NCT01381094 · Phase 2 · registry result, not featured evidence diarrhoea 20% chills 10% constipation 10% NCT01235936 · Phase 2 · registry result, not featured evidence back pain 8.3% catheter site inflammation 8.3% oropharyngeal pain 8.3% NCT04707573 · Phase 2 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 2 versus Phase 3.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dThe assessment timepoint is not available for both results.
- eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- fPopulation comparability has not been reviewed for 44 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Vadadustat
show 2 more results
show 3 more results
show 4 more results
show 3 more results
show 3 more results
show 16 more results
show 5 more results
show 11 more results
show 3 more results
show 7 more results
show 10 more results
show 5 more results
+ 26 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Desidustat's landscape · Vadadustat's landscape